Results 101 to 110 of about 52,753 (266)
People living with HIV on modern antiretrovirals do not display a pro‐atherogenic lipid profile and have similar body composition compared to healthy controls
HIV Medicine, Volume 27, Issue 1, Page 86-95, January 2026.Abstract Objectives
Alterations in lipids and apolipoproteins contribute to cardiovascular disease (CVD) and are common in people with HIV. The aim of our study was to compare lipid profiles and body composition between people with and without HIV and to explore whether any associations with HIV could be explained by socio‐demographic, clinical ...S. Savinelli, A. Heeney, W. Tinago, A. A. Garcia Leon, P. McGettrick, A. G. Cotter, I. Walsh, M. Fitzgibbon, C. A. Sabin, P. W. G. Mallon, E. R. Feeney, on behalf of the HIV UPBEAT study group +11 morewiley +1 more sourceApplication of thin layer chromatography in the analysis of efavirenz
Журнал органічної та фармацевтичної хімії, 2020 Aim. To carry out the integrated study of visualization conditions of efavirenz on TLC-plates with aplication of standard and particular colored reagents, and the chromatographic behavior of efavirenz using standard mobile phases.Oksana I. Slabiak, Iryna M. Ivanchuk, Lina Yu. Klimenko, Olena Ye. Mykytenko, Olga V. Antonenko +4 moredoaj +1 more sourceThe role of drug resistance in poor viral suppression in rural South Africa: findings from a population-based study. [PDF]
, 2020 BACKGROUND:Understanding factors driving virological failure, including the contribution of HIV drug resistance mutations (DRM), is critical to ensuring HIV treatment remains effective.Barnhart, Scott, Gilmore, Hailey J, Grignon, Jessica S, Hunt, Gillian, Liegler, Teri, Lippman, Sheri A, Mooney, Alyssa C, Prach, Lisa M, Puren, Adrian, Truong, Hong-Ha M +9 morecore Cases of antiretroviral-associated gynaecomastia reported to the National HIV & Tuberculosis Health Care Worker Hotline in South Africa [PDF]
, 2016 Background: Gynaecomastia is associated with exposure to antiretroviral therapy (ART), in particular efavirenz. There is limited data on clinical characteristics of patients with ART-associated gynaecomastia in resource-limited settings and little ...Blockman, Marc, Chisholm, Briony, Cohen, Karen, Maartens, Gary, Njuguna, Christine, Stewart, Annemie, Swart, Annoesjka, Uys, Anri +7 morecore +2 more sourcesMajor revision version 13.0 of the European AIDS Clinical Society guidelines 2025
HIV Medicine, Volume 27, Issue 1, Page 18-32, January 2026.Abstract Background
The European AIDS Clinical Society (EACS) guidelines were revised for the 21st time in 2025, with updates covering all aspects of HIV care. Key Points of the Guidelines Update
The structure of the guidelines has been reorganized into two parts: Part I focuses on the management and prevention of HIV and related infections, and Part ...Juan Ambrosioni, Laura I. Levi, Jasmini Alagaratnam, Abiu Sempere, Andrea Mastrangelo, Paolo Paioni, Cristina Mussini, Catia Marzolini, Susanne Dam Nielsen, Charles Béguelin, Steven Welch, Anna Koval, Luis Mendao, Alasdair Bamford, Alexandra Calmy, Giovanni Guaraldi, Cristiana Oprea, Esteban Martínez, Jürgen K. Rockstroh, The EACS Governing Board +19 morewiley +1 more sourceEffect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART.
Journal of Antimicrobial Chemotherapy, 2019 BACKGROUND
We previously demonstrated that etonogestrel concentrations were 82% lower in women using etonogestrel contraceptive implants plus efavirenz-based ART compared with women not receiving ART.M. Neary, C. Chappell, K. Scarsi, S. Nakalema, J. Matovu, S. Achilles, Beatrice A. Chen, M. Siccardi, A. Owen, M. Lamorde +9 moresemanticscholar +1 more sourcePerceived disabling physical pain and suicidal ideation in aging people living with HIV cured of hepatitis C: A multi‐center survey in France (ANRS CO13 HEPAVIH)
HIV Medicine, Volume 27, Issue 1, Page 106-119, January 2026.Abstract Introduction
Suicidal ideation (SI) is highly prevalent among people living with HIV (PWH) and those with chronic hepatitis C virus (HCV) infection. Individuals with long‐term HIV–HCV co‐infection face specific health challenges, including heightened physical pain.Tangui Barré, Clémence Ramier, Camelia Protopopescu, Philippe Sogni, Karine Ory, Tounes Saidi, Sophie Abgrall, Sylvie Brégigeon‐Ronot, Patrizia Carrieri, Fabienne Marcellin, the ANRS CO13 HEPAVIH Study Group, D. Salmon, L. Wittkop, P. Sogni, P. Carrieri, B. Spire, K. Ory, P. Trimoulet, J. Izopet, L. Serfaty, L. Alric, M. A. Valantin, G. Pialoux, J. Chas, K. Barange, A. Naqvi, E. Rosenthal, A. Bicart‐See, O. Bouchaud, A. Gervais, C. Lascoux‐Combe, C. Goujard, K. Lacombe, C. Duvivier, D. Neau, P. Morlat, F. Bani‐Sadr, F. Boufassa, C. Solas, H. Fontaine, L. Piroth, A. Simon, D. Zucman, F. Boué, P. Miailhes, E. Billaud, H. Aumaître, D. Rey, G. Peytavin, O. Zaeglel‐Faucher, D. Salmon, R. Usubillaga, P. Sogni, B. Bienvenu, O. Launay‐Puybasset, C. Bernasconi, A. Brunet, B. Silbermann, H. Boucher, F. Rollot, O. Zak Dit Zbar, S. Pol, C. Le Jeunne‐Ballif, P. Louergue, H. Mehawej, L. Merine‐Belardi, F. Almasi, N. Benammar, L. Alagna, S. Chaussade, L. Guillevin, B. Terris, C. Norgeux, C. Katlama, M. A. Valantin, H. Stitou, F. Caby, L. Paris, L. Schneider, R. Tubiana, A. Simon, L. Roudière, O. Benveniste, G. Breton, M. Bonmarchand, M. Kirstetter, F. Charlotte, F. Capron, V. Calvez, V. Thibaut, C. Soulie, B. Abdi, S. Lambert‐Niclot, S. Bregigeon‐Ronot, O. Zaegel‐Faucher, H. Laroche, A. Menard, E. Gaubert‐Marechal, S. Thirée, C. Tamalet, C. Hakimi, J. C. Poluzzi, C. Solas, G. Pialoux, J. Chas, L. Lassel, T. Lyavanc, S. Le Nagat, L. Slama, A. Canesti, P. Callard, B. Bachour, L. Alric, N. Sigur, D. Bonnet, M. Guivarch, K. Barange, J. M. Peron, P. Massip, L. Cuzin, M. Obada, E. Bonnet, M. Alvarez, E. Labau, M. Mularczyk, N. Bourdoncle, J. Penecy, L. Porte, F. Busato, S. Khatibi, J. Bernard, J. Selves, F. Larroquette, V. Ferrer, J. Chiabrandon, E. Rosenthal, C. Pradier, V. Mondain, P. Dellamonica, P. M. Roger, S. Ferrando, C. Ceppi, A. Naqvi, V. Rio, B. Dunais, B. Prouvost, F. De Salvadore‐Guillouet, I. Prebost, J. Durant, P. Pugliese, J. F. Michels, M. C. Saint‐Paul, C. Partouche, K. Nerini, O. Bouchaud, S. Abgrall, I. Zamord, F. Bidegain, M. Azghay, C. Rouyer, M. Tatay, F. Mechai, A. Martin, Y. Baazia, V. Iwaka‐Bande, A. Gerber, A. Bicart‐See, D. Garipuy, M. J. Ferro‐Collados, F. Gaches, F. Abravanel, F. Larroquette, J. Chiabrandon, A. Gervais, Y. Yazdanpanah, D. Henin, M. Bertine, M. Onambele, G. Peytavin, C. Lascoux‐Combe, T. Kandel, C. Pintado, J. M. Molina, C. Gatey, S. Gallien, W. Rozenbaum, M. Lafaurie, A. L. Munier, D. Ponscarme, M. Previllon, N. Colin De Verdière, M. G. Tateo, P. Palmer, A. Gabassi, R. Amarsy, M. C. Mazeron, K. Lacombe, J. Krause, D. Wendum, D. Fofana, C. Goujard, Y. Quertainmont, E. Teicher, L. Escaut, O. Derradji, C. Pallier, F. Veillet, L. Mouna, O. Lortholary, C. Duvivier, C. Rouzaud, M. Shoai Tehrani, S. Boucly, G. Obenga, J. P. Viard, E. Gardiennet, A. Mélard, D. Neau, A. Ochoa, E. Blanchard, C. Cazanave, M. Dupon, H. Dutronc, F. Dauchy, H. Wille, P. Bioulac‐Sage, P. Trimoulet, P. Morlat, D. Lacoste, F. Bonnet, N. Bernard, M. Hessamfar, F. Paccalin, C. Martell, M. C. Pertusa, M. Vandenhende, P. Mercié, T. Pistone, M. C. Receveur, M. Méchain, P. Duffau, C. Rivoisy, I. Faure, D. Malvy, J. Roger‐Schmeltz, D. Dondia, P. Bioulac‐Sage, P. Trimoulet, J. L. Pellegrin, E. Lazzaro, P. Bioulac‐Sage, P. Trimoulet, D. Zucman, C. Majerholc, J. E. Kahn, S. Hilaire, M. Brollo, F. Boué, S. Abgrall, J. Polo Devoto, I. Kansau, V. Chambrin, C. Pignon, C. Gatey, M. Favier, C. Deback, C. Vauloup, C. Pailler, F. Veillet, L. Mouna, J. L. Lopez Zaragoza, Y. Lévy, J. D. Lelièvre, A. S. Lascaux, S. Scerra, M. Bouvier‐Alias, E. Billaud, F. Raffi, C. Allavena, V. Reliquet, D. Boutoille, C. Biron, M. Lefebvre, N. Hall, S. Bouchez, C. Bernaud, O. Mounoury, A. Rodallec, L. Le Guen, P. Miailhes, D. Peyramond, C. Chidiac, F. Ader, F. Biron, A. Boibieux, L. Cotte, T. Ferry, T. Perpoint, M. Amiri, F. Valour, J. Koffi, F. Zoulim, F. Bailly, P. Lack, M. Maynard, S. Radenne, C. Augustin‐Normand, E. Vassel, T. T. Le‐Thi, L. Piroth, P. Chavanet, M. Duong Van Huyen, M. Buisson, A. Waldner‐Combernoux, S. Mahy, A. Fillion, H. Aumaître, M. Jean, A. Eden, M. Medus, M. Saada, S. Gaba, F. Bani‐Sadr, D. Lambert, Y. Nguyen, J. L. Berger, C. Rouger, V. Brodard, D Rey, M. Partasani, C. Cheneau, M. Priester, C. Bernard‐Henry, E. de Mautort, A. Ertle, F. Jegou, A. Fush, P. Gantner, S. Fafi‐Kremer, L. Pinheiro, F. Roustand, I. Kmiec, L. Traore, S. Le Puil, M. G. Tateo, S. Benothame, C. Pomes, C. Louisin, M. Mole, A. Adda, P. Thibaut, S. Poirier, R. Ben Rayana, M. P. Pietri, V. Le Baut, Y. Cuvillier, M. Alabatanah, F. Barret, F. Juster, C. Chesnel, D. Beniken, M. Sebire‐Le Cam, R. Monard, F. Badji, S. Caldato, T. Rojas Rojas, A. S. Ritleng, A. Ivanova, L. Chalal, Z. Julia, M. Cavellec, C. Chevalier, E. Paredes‐Manyari, S. Breau, N. Boughdiri, P. Fischer, C. Charles, S. Ogoudjobi, C. Brochier, V. Thoirain‐Galvan, L. Traore, S. Chaussee, S. Benothmane, A. Sondro, O. Camou, V. Godard, M. Kai, C. Gilbert, M. Pailler, L. Merchadou, L. Esterle, K. Ory, S. Gillet‐Rousseau, C. Khan, L. Abbad, M. Chalouni, V. Conte, F. Marcellin, R. Knight, M. Mora, C. Protopopescu, P. Roux, T. Barré +402 morewiley +1 more sourcePositive Outcomes of HAART at 24 Months in HIV-Infected Patients in Cambodia. [PDF]
, 2007 OBJECTIVES: African and Asian cohort studies have demonstrated the feasibility and efficacy of HAART in resource-poor settings. The long-term virological outcome and clinico-immunological criteria of success remain important questions.Bartlett, Bartlett, Bourgeois, Calmy, Calmy, Carrieri, Carrieri, Coetzee, Colebunders, Colebunders, Dabis, Ferradini, Gill, Gonzalez de, Grabar, Ivers, Kumarasamy, Laurent, Laurent, Lawn, Lawn, Lawn, Le Moing, Ly, Madec, Marzolini, Orrell, Pasquier, Rouet, Rouzioux, Severe, Tassie, Van Heeswijk, Weidle, Wu, Zhou +35 morecore +2 more sourcesImpact on weight of a Doravirine switch in people living with HIV
HIV Medicine, Volume 27, Issue 1, Page 136-145, January 2026.Abstract Background and Objective
Doravirine is among the first‐line recommended treatments for people living with HIV (PLHIV) in the 2025 EACS guidelines. As opposed to tenofovir alafenamide or anti‐integrase, its use was not associated with weight gain in clinical trials, but limited data are currently available in real life. In this cohort study, we Nina Garofoli, Philippe Flandre, Jean‐Paul Vincensini, Quentin Richier, Priscille Couture, Karine Lacombe, Gilles Pialoux, Jean‐Luc Meynard +7 morewiley +1 more source
